Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6721 to 6735 of 7669 results

  1. Belatacept for the prevention of organ rejection in kidney transplantation [ID87]

    Discontinued [GID-TAG239]

    Technology appraisal guidance
    Discontinued

  2. Canagliflozin for treating chronic kidney disease in people with type 2 diabetes [ID1653]

    In development [GID-TA10555] Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Vorapaxar for reducing atherothrombotic events after a myocardial infarction or in peripheral vascular disease [ID616]

    Discontinued [GID-TAG493]

    Technology appraisal guidance
    Discontinued

  4. Rivogenlecleucel for treating haematological cancers in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1601]

    In development [GID-TA10467] Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Community nursing care settings

    Discontinued [GID-SGWAVE0700]

    Safe staffing guideline
    Discontinued

  6. Diagnostic services

    Discontinued [GID-CGWAVE0773]

    NICE guideline
    Discontinued

  7. Vemurafenib for treating resected BRAF V600 mutation-positive melanoma [ID1250]

    Discontinued [GID-TA10213]

    Technology appraisal guidance
    Discontinued

  8. Apalutamide for treating non-metastatic, hormone-relapsed prostate cancer [ID1174]

    Discontinued [GID-TA10377]

    Technology appraisal guidance
    Discontinued

  9. Ridaforolimus for the maintenance treatment of metastatic soft tissue or bone sarcoma [ID415]

    Discontinued [GID-TAG431]

    Technology appraisal guidance
    Discontinued

  10. Nivolumab for previously treated gastric or gastro-oesophageal junction cancer [ID1118]

    Discontinued [GID-TA10151]

    Technology appraisal guidance
    Discontinued

  11. Pembrolizumab for gastric or gastroesophageal junction adenocarcinoma [ID1305]

    Discontinued [GID-TA10244]

    Technology appraisal guidance
    Discontinued

  12. Nivolumab with radiation therapy for previously untreated glioblastoma multiforme [ID1562]

    Discontinued [GID-TA10443]

    Technology appraisal guidance
    Discontinued

  13. Gastroenteropancreatic neuroendocrine tumours (somatostatin, non-progressive) - lutetium-177 DOTATATE [ID857]

    Discontinued [GID-TA10033]

    Technology appraisal guidance
    Discontinued

  14. Etirinotecan pegol for treating breast cancer with brain metastases [ID881]

    Discontinued [GID-TA10066]

    Technology appraisal guidance
    Discontinued

  15. Pazopanib for the second line treatment of advanced and/or metastatic renal cell carcinoma [ID70]

    Discontinued [GID-TAG398]

    Technology appraisal guidance
    Discontinued